Optimizing Vaccine Allocation to Combat the COVID-19 Pandemic
暂无分享,去创建一个
M. L. Li | D. Bertsimas | J. K. Ivanhoe | A. Jacquillat | A. Previero | O. S. Lami | H. T. Bouardi | D. Bertsimas | A. Jacquillat | O. S. Lami | M. Li | Hamza Tazi Bouardi | Joshua Ivanhoe | Alessandro Previero
[1] Ira M. Longini,et al. Optimizing Vaccine Allocation at Different Points in Time during an Epidemic , 2010, PloS one.
[2] Lynnette Brammer,et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[3] Jian-ming Wang,et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China , 2020, Science China Life Sciences.
[4] S. Plotkin,et al. The complexity and cost of vaccine manufacturing – An overview , 2017, Vaccine.
[5] Richard C. Larson,et al. Multiregional Dynamic Vaccine Allocation During an Influenza Epidemic , 2013 .
[6] Ralph L. Keeney,et al. Repeated Commit-or-Defer Decisions with a Deadline: The Influenza Vaccine Composition , 2008, Oper. Res..
[7] M. L. Li,et al. Forecasting COVID-19 and Analyzing the Effect of Government Interventions , 2020, medRxiv.
[8] Anne Kimball,et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.
[9] D. Bertsimas,et al. From predictions to prescriptions: A data-driven response to COVID-19 , 2020, Health Care Management Science.
[10] W. Cornwall. Just 50% of Americans plan to get a COVID-19 vaccine. Here’s how to win over the rest , 2020 .
[11] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[12] N. Lurie,et al. Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.
[13] Xiaolong Qi,et al. Real estimates of mortality following COVID-19 infection , 2020, The Lancet Infectious Diseases.
[14] J. Medlock,et al. Optimizing Influenza Vaccine Distribution , 2009, Science.
[15] G. Chowell,et al. Modeling Optimal Age-Specific Vaccination Strategies Against Pandemic Influenza , 2011, Bulletin of Mathematical Biology.
[16] Stephen L. Jones,et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population , 2020, BMJ Open.
[17] Li Yan,et al. Evaluation of the clinical characteristics of suspected or confirmed cases of COVID-19 during home care with isolation: A new retrospective analysis based on O2O , 2020, medRxiv.
[18] Ezekiel J Emanuel,et al. Who Should Get Influenza Vaccine When Not All Can? , 2006, Science.
[19] M. Halloran,et al. Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. , 2005, Journal of theoretical biology.
[20] Z. Memish,et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.
[21] Alan S. Perelson,et al. Optimization of Influenza Vaccine Selection , 2005, Oper. Res..
[22] Shibo Jiang,et al. Current development of COVID-19 diagnostics, vaccines and therapeutics , 2020, Microbes and Infection.
[23] Soo-Haeng Cho,et al. The Optimal Composition of Influenza Vaccines Subject to Random Production Yields , 2010, Manuf. Serv. Oper. Manag..
[24] David Simchi-Levi,et al. A Game-Theoretic Model of International Influenza Vaccination Coordination , 2013, Manag. Sci..
[25] Gerardo Chowell,et al. Adaptive Vaccination Strategies to Mitigate Pandemic Influenza: Mexico as a Case Study , 2009, PloS one.
[26] M. Lipsitch,et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.
[27] A. Langworthy,et al. An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.
[28] Rommert Dekker,et al. Literature review: The vaccine supply chain , 2017, Eur. J. Oper. Res..
[29] Jorge Nocedal,et al. A trust region method based on interior point techniques for nonlinear programming , 2000, Math. Program..
[30] M. Bajpai,et al. Study of Non-Pharmacological Interventions on COVID-19 Spread , 2020, medRxiv.
[31] Yonatan H. Grad,et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.
[32] Nico Vandaele,et al. A review of integrated supply chain network design models: Key issues for vaccine supply chains , 2016 .
[33] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[34] Sheldon Howard Jacobson,et al. Pediatric vaccine procurement policy: The monopsonist's problem , 2011 .
[35] Brian T. Denton,et al. Optimal two-phase vaccine allocation to geographically different regions under uncertainty , 2014, Eur. J. Oper. Res..
[36] Marc Lipsitch,et al. Quantifying bias of COVID-19 prevalence and severity estimates in Wuhan, China that depend on reported cases in international travelers , 2020, medRxiv.
[37] Jeffrey W. Herrmann,et al. Montgomery County's Public Health Service Uses Operations Research to Plan Emergency Mass Dispensing and Vaccination Clinics , 2006, Interfaces.
[38] Sheldon H Jacobson,et al. Stockpile levels for pediatric vaccines: how much is enough? , 2006, Vaccine.
[39] Rubén A. Proaño,et al. An analysis of the pediatric vaccine supply shortage problem , 2006, Health care management science.
[40] An Pan,et al. Evolving Epidemiology and Impact of Non-pharmaceutical Interventions on the Outbreak of Coronavirus Disease 2019 in Wuhan, China , 2020, medRxiv.
[41] Hannah R. Meredith,et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.
[42] Matt J. Keeling,et al. Optimal but unequitable prophylactic distribution of vaccine , 2012, Epidemics.
[43] Cecile Viboud,et al. Vaccinating to Protect a Vulnerable Subpopulation , 2007, PLoS medicine.
[44] Stephen L. Jones,et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population , 2020, BMJ Open.
[45] Jeffrey C. Lagarias,et al. Convergence Properties of the Nelder-Mead Simplex Method in Low Dimensions , 1998, SIAM J. Optim..
[46] E. Emanuel,et al. An ethical framework for global vaccine allocation , 2020, Science.
[47] Ozgur M. Araz,et al. Geographic prioritization of distributing pandemic influenza vaccines , 2012, Health care management science.
[48] Wenwu Sun,et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019 , 2020, medRxiv.
[49] M. Koopmans,et al. SARS-CoV-2 infection in 86 healthcare workers in two Dutch hospitals in March 2020 , 2020, medRxiv.
[50] M. Halloran,et al. Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States , 2009, American journal of epidemiology.
[51] Matthew W. Tanner,et al. Finding optimal vaccination strategies under parameter uncertainty using stochastic programming. , 2008, Mathematical biosciences.
[52] Robert J. Cerfolio,et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City , 2020, medRxiv.
[53] Peng Sun,et al. Selfish Drug Allocation for Containing an International Influenza Pandemic at the Onset , 2009, Oper. Res..
[54] M. Elizabeth Halloran,et al. Optimal Vaccine Allocation for the Early Mitigation of Pandemic Influenza , 2013, PLoS Comput. Biol..
[55] I. Longini,et al. An optimization model for influenza A epidemics , 1978 .
[56] C. Viboud,et al. Adaptive vaccination strategies to mitigate pandemic influenza , 2009, PLoS currents.
[57] Cecile Viboud,et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza , 2012, Proceedings of the National Academy of Sciences.
[58] Barney S. Graham,et al. Rapid COVID-19 vaccine development , 2020, Science.
[59] Stefan Wager,et al. Valuing Lead Time , 2013 .
[60] G. Tiram,et al. Immune-mediated approaches against COVID-19 , 2020, Nature Nanotechnology.
[61] Judith R Kaufmann,et al. Vaccine supply chains need to be better funded and strengthened, or lives will be at risk. , 2011, Health affairs.
[62] Steven G. Krantz,et al. Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling , 2020, Infection Control & Hospital Epidemiology.
[63] R. Watson,et al. On an epidemic in a stratified population , 1972, Journal of Applied Probability.
[64] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[65] David Simchi-Levi,et al. Supply Chain Coordination and Influenza Vaccination , 2008, Oper. Res..
[66] David M. Wirth,et al. COVID-19 vaccine development and a potential nanomaterial path forward , 2020, Nature Nanotechnology.
[67] Tapas K. Das,et al. A predictive decision-aid methodology for dynamic mitigation of influenza pandemics , 2011, OR Spectr..
[68] Nan Yang,et al. Competition Under Generalized Attraction Models: Applications to Quality Competition Under Yield Uncertainty , 2009, Manag. Sci..
[69] Sarang Deo,et al. Consumption Externality and Yield Uncertainty in the Influenza Vaccine Supply Chain: Interventions in Demand and Supply Sides , 2012, Manag. Sci..